The use of blockbuster weight loss drugs has surged among young women, for whom the treatments can often be "liberating." ...

Cencora is now targeting an 8% to 10% rise in revenue for the full fiscal year, a lift from its previous guidance for 7% to 9% growth. Sales are expected to rise 9% to 11% in its U.S. healthcare ...

While Wegovy (semaglutide) sales more than doubled to DKK 19.87 billion ($2.78 billion) in the three-month period, that was slightly below estimates and Novo Nordisk said is now anticipating ...

Cencora, Inc. (NYSE: COR) reported that in its fiscal year 2025 first quarter ended December 31, 2024, revenue increased 12.8 percent year-over-year to $81.5 billion. On the basis of U.S. generally ...

The GLP-1 drug, exenatide, has no positive impact on the movement, symptoms or brain imaging of people with Parkinson's ...

Eli Lilly Chief Corporate Brand Officer Lina Polimeni on how the brand differentiates itself in the crowded pharma market, ...

The weight loss injection Mounjaro is a new treatment that can now be delivered to customers' homes by a new clinic service offered by Morrisons.

Owens & Minor shares have plummeted over 50% in the past year, with a recent 35% drop due to poor results and significant impairment.

Viking Therapeutics is a clinical-stage biotech company focused on developing weight-loss therapies. Read why I rate VKTX ...

Toyota Motor sold 10.8 million vehicles globally in 2024, retaining its position as the world's biggest carmaker. The Japanese automakers had announced a plan to combine in December. Novo's Wegovy and ...

A solid economy and still-too-high inflation argue for holding interest rates steady until more progress is made in slowing price growth, Federal Reserve Vice Chair Philip Jefferson said on Tuesday ...

The GLP-1 drug, exenatide, has no positive impact on the movement, symptoms or brain imaging of people with Parkinson's, finds a new study led by UCL researchers.